TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
2019年9月7日 更新者:Ghadeer abdelrazzak mohammed、Assiut University
Transcription Factor 7 Like 2 Gene Polymorphism and Advanced Glycation End Products as Risk Factors for Diabetic Nephropathy
- To study genotypic distribution of the TCF7L2 gene polymorphism in Diabetic nephropathy.
- To assess level of AGEs and Insulin in patients with Diabetic nephropathy.
- To study correlation between polymorphism of the TCF7L2 gene, AGEs, Insulin and clinical characteristics in patients with diabetic nephropathy
研究概览
地位
未知
条件
详细说明
Diabetic nephropathy is one of microvascular complications of diabetes mellitus.
DN is a multifactorial disorder that occurs in one third of patients with long standing DM.
DN is one of the most serious complications that being a major contributing factor to end-stage renal disease and death in diabetic patients.
The earliest clinical indication of DN is the appearance of microalbuminuria.
Detection of diabetic nephropathy as early as possible, is the best chance of delaying progression to ESRD.
Thus, screening for microalbuminuria is recommended annually immediately after a diagnosis of diabetes.
Transcription factor 7-like 2 is a highly variable transcription factor, which is a key component of the Wnt-signaling pathway and plays a role in the regulation of insulin secretion by pancreatic beta cells and the maintenance of glucose homeostasis.
TCF7L2 rs7903146 polymorphism is more associated with T2DM which mediated by decreased insulin secretion associated with defects in insulin processing, reduced effects of glucagon-like peptide-1, increased hepatic glucose production and insulin resistance.
The mutant TT genotype and the T allele frequency was associated with diabetic patients who developed nephropathy.
Advanced glycation end products are generated by the non-enzymatic reaction of amino groups in DNA and proteins with reducing sugars.
AGEs accumulate in glomerular basement membrane.
The AGEs-RAGE interaction is a causative factor for DN through activating a series of intracellular signal-cascade pathways which induce the generation of further signalling factors, such as vascular endothelial growth factor, transforming growth factor B, nuclear factor-κβ.
Those signalling factors cause mesangial expansion and glomerulosclerosis.
研究类型
观察性的
注册 (预期的)
100
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 75年 (成人、年长者)
接受健康志愿者
不适用
有资格学习的性别
全部
取样方法
非概率样本
研究人群
60 diabetic patients: Diagnosis of DM was based on the American Diabetes Association Criteria:
-The diabetic patients will be classified into 2 subgroups:
- 30 Diabetic patients without any microvascular or macrovascular complications.
- 30 Diabetic patients with pure nephropathy not having other microvascular or macrovascular complications.
- 20 patients diagnosed as prediabetes:
- Beside 20 Apparent healthy subjects as control group.
描述
Inclusion Criteria:
- diabetic nephropathy
- clinical diagnosis of prediabetes
- Type 2 diabetic patients
Exclusion Criteria:
- cardiovascular disease
- diabetic neuropathy
- diabetic retinopathy
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of diabetic nephropathy
大体时间:one year
|
find a link between genetic polymorphism of TCF7L2 and the risk of developing nephropathy in diabetic patients. Nephropathy is defined Albumin/creatinine ratio > 30 mg/gm creat. |
one year
|
|
Number of patients with genotype TCF7L2 by PCR
大体时间:5 years
|
the prevalence of TCF7L2, in the diabetic patient, and compared to the values found in the general population. the TCF7L2 genes will be evaluated by PCR-RFLP |
5 years
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Gawandi S, Gangawane S, Chakrabarti A, Kedare S, Bantwal K, Wadhe V, Kulkarni A, Kulkarni S, Rajan MGR. A Study of Microalbuminuria (MAU) and Advanced Glycation End Products (AGEs) Levels in Diabetic and Hypertensive Subjects. Indian J Clin Biochem. 2018 Jan;33(1):81-85. doi: 10.1007/s12291-017-0638-5. Epub 2017 Feb 1.
- Adamska E, Kretowski A, Goscik J, Citko A, Bauer W, Waszczeniuk M, Maliszewska K, Paczkowska-Abdulsalam M, Niemira M, Szczerbinski L, Ciborowski M, Gorska M. The type 2 diabetes susceptibility TCF7L2 gene variants affect postprandial glucose and fat utilization in non-diabetic subjects. Diabetes Metab. 2018 Sep;44(4):379-382. doi: 10.1016/j.diabet.2017.05.001. Epub 2017 May 31. No abstract available.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (预期的)
2019年9月1日
初级完成 (预期的)
2020年9月1日
研究完成 (预期的)
2020年10月1日
研究注册日期
首次提交
2019年9月3日
首先提交符合 QC 标准的
2019年9月7日
首次发布 (实际的)
2019年9月10日
研究记录更新
最后更新发布 (实际的)
2019年9月10日
上次提交的符合 QC 标准的更新
2019年9月7日
最后验证
2019年9月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.